A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors (NCT07020117)
NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- City of Hope — Duarte, California
- Hoag Memorial Hospital Presbyterian — Irvine, California
- Biogenix Molecular, LLC — Miami, Florida
- Advent Health Medical Group Radiation Oncology at Central Florida — Orlando, Florida
- University of Iowa — Iowa City, Iowa
- University of Kansas — Westwood, Kansas
- United Theranostics — Glen Burnie, Maryland
- BAMF Health — Grand Rapids, Michigan
- Icahn School of Medicine at Mt. Sinai — New York, New York
- UPMC — Pittsburgh, Pennsylvania
- MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (978) 208-3986
Email: AKY-1189-01inquiries@aktisoncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Carcinoma Bladder
- Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer — Baltimore, Maryland
- Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer — Houston, Texas
- Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy — Gainesville, Florida
- Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer — Philadelphia, Pennsylvania
Explore by condition: All Urothelial Carcinoma Bladder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.